Dr. Richard Burt, MD, is Chief of the Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine. Dr. Burt pioneered the use of hematopoietic stem cells to treat autoimmune diseases. He performed and continues to do stem cell transplants in numerous animal autoimmune diseases for preclinical data to support human clinical trials.
Dr. Burt performed either America's first or the world's first autologous (one's own) hematopoietic stem cell transplants for numerous immune mediated diseases including rheumatoid arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, Crohn's disease, polymyositis, bullous pemphigus, chronic inflammatory demyelinating polyneuropathy, neurovascular Behcets, neurovascular or pulmonary Sjogrens, Wegners granulmatosus, and Arron's syndrome (immune-mediated blindness).
Northwestern University's Division of Immunotherapy, under Dr. Burt's direction, has performed more hematopoietic stem cell transplants for autoimmune and immune mediated diseases than any other center in the world.
Dr. Burt is the leader of randomized controlled trials currently ongoing in America for lupus, crohn's disease, multiple sclerosis, and systemic scleroderma. These trials are: LIST (Lupus Immunsuppression versus Transplant), ASSIST (American Scleroderma Stem cell vs Immune Suppression Trial), KISS ( Crohns Immune Suppression vs Stem cell Transplant), and MIST ( Multiple sclerosis Immune suppression vs Stem cell Transplant).
Dr. Burt has also performed the World's first allogeneic (another person's ) stem cell transplant for rheumatoid arthritis and has FDA approved allogeneic (sibling or cord blood) stem cell transplant trials ongoing for systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis,and crohn's disease. Current clinical trials being developed by Dr. Burt based on animal stem cell transplant models in Dr. Burt's laboratory include allogeneic stem cell transplants for amyotrophic lateral scerosis (ALS), primary biliary cirrhosis (PBC), and Autism. Again based on animal results, Dr. Burt is also using stem cells to treat patients with peripheral vascular disease (PVD) on FDA approved clinical trials and is developing a stem cell transplants protocol for chronic congestive heart failure.
Dr. Burt's division works closely with world recognized physician investigators from numerous departments and divisions at the Northwestern University Feinberg School of Medicine in development of these studies and managing the care of these patients.